IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. - Wikidata - wikimedia - TriplyDB

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

http://www.wikidata.org/entity/Q37520432

about

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin.EMT and inflammation: inseparable actors of cancer progression.Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Pharmacological and immunological targeting of tumor mesenchymalization.Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.IL-8 regulates the stemness properties of cancer stem cells in the small-cell lung cancer cell line H446

P2860

Q33638144-A2C35207-595F-41D7-BCA1-940334F2E49C Q33869755-3B3E637C-BB31-49F2-AF9D-DE730D850134 Q37330932-0CE96C69-E333-45BC-86CF-A256F05BEED0 Q38745430-91067C3A-C64E-46AE-BF14-86E2C5DAA750 Q39029043-E4F096A1-CC4A-4650-80F8-9C54CDA29768 Q39435498-AE4877FC-C8F9-4065-B7DA-0853EB8545D9 Q40074028-B66B9BE2-F6CF-4755-81EE-A7A9715DBA83 Q49900625-1F7B944E-1647-48C0-B7BF-75BB6A61C5B8 Q52540247-6EDEBD09-013C-4DE7-9FA3-52CB7DA74FAE Q58751032-2070D671-7D23-41EA-B04E-D2050C4FC4E3

P2860

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

http://www.wikidata.org/entity/Q37520432

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

@en

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

@nl

type

label

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

@en

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

@nl

prefLabel

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

@en

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

@nl

P1433

Q37520432-50C0E78F-CF03-46E8-8803-0377A71368E5

P1476

Q37520432-E691566C-A1ED-48FA-A6A9-C0661AB6AB52

P2093

Q37520432-077D9367-B11E-46A0-95C2-D40291D0FB4F

Q37520432-1E3BC879-0DF6-420B-9DD9-8A789F439B9C

Q37520432-690D71B0-34FE-42ED-8806-1C36E5F69C24

Q37520432-8FC067B6-5EC8-4C31-A29B-3560BB251A39

Q37520432-901ECF57-BC4C-4DB3-85B6-B15321AAD7E4

Q37520432-C1D0BC23-C3CF-4E03-A3E0-6EF6C677F4B9

P2860

Q37520432-0B6809C5-F8CF-4638-8B57-6484625A80A5

Q37520432-11EA538F-CF88-4E41-BA01-73526CBA9388

Q37520432-15C77D6B-6090-4921-A5CE-D7E5A2226F26

Q37520432-169CE2F3-3ACE-45EC-90E4-8A5BAF2DF720

Q37520432-319C14EC-B778-4173-86D8-078F5D8F7C5A

Q37520432-3942AB1A-3C91-45FA-8E13-1402D07C69FE

Q37520432-3B153917-119E-4A86-9205-79E07DE128DA

Q37520432-3E7859C3-1365-4DC2-9B6D-646C2480A4D7

Q37520432-3EEA4341-1AFF-4966-BCDA-005EB784A348

Q37520432-4643580F-3E0C-4696-B6EA-CB24ECEED369

P304

Q37520432-ADFD555D-C500-4650-A331-6FC5B9EB522C

P31

Q37520432-6B03E055-7D76-4F80-AEC1-578BE0CB13ED

P356

Q37520432-D092B6A9-62DE-4E19-9E3F-F4000E93BD54

P407

Q37520432-0BBFE285-641C-4D22-B46D-D12C47DD76D7

P433

Q37520432-8F2D5435-07B0-40F1-A557-90D2A1710F77

P478

Q37520432-51E3858A-D820-4638-8B2E-36A5B117AA71

P577

Q37520432-90850FC7-A24C-407D-B4D1-DD059073D079

P698

Q37520432-20980A41-A73C-48B2-9FE8-9D421BAD95F5

P932

Q37520432-3A183C0B-12BC-4B61-8960-04E84E353E97

P356

ONCOTARGET.9662

P1433

P1476

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.

@en

P2093

Charli Dominguez

http://www.w3.org/2001/XMLSchema#string

Claudia Palena

http://www.w3.org/2001/XMLSchema#string

Duane H Hamilton

http://www.w3.org/2001/XMLSchema#string

Justin M David

http://www.w3.org/2001/XMLSchema#string

Kristen K McCampbell

http://www.w3.org/2001/XMLSchema#string

Romaine I Fernando

http://www.w3.org/2001/XMLSchema#string

P2860

A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Epithelial-mesenchymal transitions in development and disease

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Erlotinib in previously treated non-small-cell lung cancer

P304

42031-42044

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.9662

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27248176

http://www.w3.org/2001/XMLSchema#string

P932

5173114

http://www.w3.org/2001/XMLSchema#string